Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
SAN DIEGO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Evofem, a biotechnology company focused on the development and commercialization of women's health products, announced today that it met with representatives of the U.S. Food and Drug Administration ("FDA") in a Pre-IND (Investigational New Drug) meeting for its lead product, Amphora to be evaluated for the prevention of recurrence of Bacterial Vaginosis (BV). Research suggests Amphora, a vaginally delivered topical gel, works through a novel mechanism of action against several bacterial and viral organisms. As a result of this meeting, Evofem will be developing a formal research protocol to begin clinical studies.
Saundra Pelletier, Chief Executive Officer of Evofem, said, "I am pleased with the guidance we received and the clarification of the work necessary to file an Investigational New Drug Application. This area of development is consistent with our platform of finding and developing promising healthcare solutions that address unmet needs for women worldwide."
A New Drug Application for Amphora as a non-hormonal, vaginal gel contraceptive was accepted by the United States Food and Drug Administration (FDA) in July of 2015.
About Evofem
Evofem Holdings, Inc. seeks to address a growing global contraceptive market, while delivering effective, woman-controlled products with global distribution. Evofem Holdings, Inc. has two lead product candidates: Amphora, a non-hormonal contraceptive gel, and the Nestorone Ring, a one-year contraceptive vaginal ring, both of which have completed Phase III clinical studies.
For further information on the Company, please visit: www.evofem.com
About Amphora
Amphora is a non-hormonal vaginal gel. In addition to the regulatory filing for approval as a contraceptive, Amphora is being investigated for microbicidal properties to develop a potential multipurpose prevention technology. Amphora works by restoring the vaginal pH levels to those consistent with a healthy vaginal environment.
CONTACT: Media Inquiries
Nicole Beckstrand
[email protected]
858.550.1900 ext. 250
